Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, March 13, 2014 9:07:07 AM
Again, I am not a medical researcher and out of my league on the details, but what I gleaned is that while the nano micelles show a promising future, as with all compounds placed in the physiological system, there are safety concerns.
I think the paper suggests the most logical concerns are uptake in parts of the immune system, as with monocytes and macrophages accumulation in lymph nodes and the spleen (I am surmising here). Also some concerns over the degree of allergic reactions and/or inflammatory responses, particularly with continuous exposure or long-term use.
Other papers suggest that toxicities exhibited during in-vitro testing are not typically appearing or obvious in in-vivo and suggest the body can tolerate the compounds in general. The gist I got was that if no or low apparent toxicities are initially seen, due diligence would dictate investigation the effect of multiple or prolonged dosages to look for accumulation and/or other physiological responses as indicated above. Sounds like pure common sense to me.
The take-away for me is that the duration of a highly complete and thorough toxicity investigation could have a need to be expanded, even if good news is shown initially.
However, it also appears that some of the extended dosing concerns might be more associated with anti-cancer therapeutic drug deliveries that many need to occur in many courses distributed over many years. Viral infections are more temporally acute issues.
As a side note, the attachment of the target ligands as discussed in the CRC publication also appear self-assembling such that they can produce a base carrier nanomicelle material that has extended shelf-life, where upon a new virus could be quickly engaged by simply adding the desired target ligand to existing batches of ‘blank’ nanovircides waiting on the shelves to be essentially programmed.
That would be wonderful and again, it means that Nanoviricides may actually be the most effective anti-pandemic defense system the world has seen under development to date.
The more I investigate this potential life saving technology, the more I am impressed.
Have a great day!
HS
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM